Scrying Biotech
Long only, biotech, micro-cap, small-cap

Cyclacel Rising

Ahead of what could be a major milestone at the 55th Annual Meeting of the American Society of Hematology, Cyclacel's (NASDAQ:CYCC) stock price has risen steadily as I predicted it would. The pace of appreciation has been in lockstep with a steady drumbeat of good news over the past several months.

(click to enlarge)

That trend is likely to continue, but before I make the case for an explosive move to the upside, I want to briefly address a change to my investment philosophy that has implications far beyond my risk profile as it will impact the number of articles I author here on Seeking Alpha.

Many professional advisors caution that a balanced portfolio across multiple sectors is...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details